Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × HR+/HER2- Breast Cancer × Fulvestrant × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 29 Ovarian Neoplasms 4 Endometrial Neoplasms 4 Uterine Cervical Neoplasms 3 Squamous Cell Carcinoma of Head and Neck 3 Neoplasms 3 Neoplasms by Site 2 Hereditary Sensory and Autonomic Neuropathies 2 Head and Neck Neoplasms 2 Breast Diseases 2 Advanced Solid Tumors 2 Triple Negative Breast Neoplasms 1 Solid Tumor, Adult 1 Prostatic Neoplasms 1 Neoplasm Metastasis 1 Melanoma 1 HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer 1 HR+/HER2- Breast Cancer 1 HER2-positive Metastatic Breast Cancer 1 HER2-positive Breast Cancer 1 Fallopian Tube Neoplasms 1 Estrogen Receptor Positive Breast Cancer 1 Esophageal Squamous Cell Carcinoma 1 Colorectal Neoplasms 1 Carcinoma, Transitional Cell 1 Carcinoma, Ovarian Epithelial 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Ductal, Breast 1 Brain Neoplasms 1 Anatomic Stage II Breast Cancer AJCC v8 1

Interventions

Letrozole 1 Fulvestrant 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06998407 2026-02-20

AVZO-023-1001

Avenzo Therapeutics, Inc.

Phase 1/2 Recruiting

HR+/HER2- Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡